Product Description
Accendatech is developing ACT-001 as a treatment for recurrent glioblastoma multiforme (GBM). (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05053880)
Mechanisms of Action: NF-kappaB Inhibitor,STAT3 Inhibitor,PKM2 activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Accendatech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Unknown Location
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Glioblastoma|Glioma|Idiopathic Pulmonary Fibrosis|Lung Diseases, Interstitial
Phase 1: Brain Cancer|Nose Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12616000228482 | P1 |
Completed |
Nose Cancer|Glioblastoma |
2022-06-20 |
|
| ACTRN12621001172897 | P1 |
Recruiting |
Brain Cancer|Glioblastoma |
2022-04-29 |
|
| CTR20232173 | P2 |
Not yet recruiting |
Glioma |
None |
|
| ACTRN12619001643167 | P2 |
Recruiting |
Lung Diseases, Interstitial|Idiopathic Pulmonary Fibrosis |
None |